CN111419956A - A Chinese medicinal composition for treating hepatitis B - Google Patents

A Chinese medicinal composition for treating hepatitis B Download PDF

Info

Publication number
CN111419956A
CN111419956A CN202010464482.1A CN202010464482A CN111419956A CN 111419956 A CN111419956 A CN 111419956A CN 202010464482 A CN202010464482 A CN 202010464482A CN 111419956 A CN111419956 A CN 111419956A
Authority
CN
China
Prior art keywords
parts
weight
treating hepatitis
traditional chinese
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010464482.1A
Other languages
Chinese (zh)
Inventor
仲崇允
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010464482.1A priority Critical patent/CN111419956A/en
Publication of CN111419956A publication Critical patent/CN111419956A/en
Priority to CN202110536835.9A priority patent/CN113209198A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/754—Evodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Abstract

The invention discloses a traditional Chinese medicine for treating hepatitis B, which is prepared from the following raw material medicines in parts by weight: 1-3 parts by weight of catechu; 5-10 parts by weight of nutgall, rhizoma cimicifugae and pseudo-ginseng; 7-15 parts of silybum marianum; 10-20 parts of trichosanthes root and giant knotweed; 15-30 parts of penthorum chinense pursh, ampelopsis grossedentata, evodia lepta, blumea balsamifera and ricefield eel vine.

Description

A Chinese medicinal composition for treating hepatitis B
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating hepatitis B.
Background
Hepatitis B is part of the manifestation of the pathophysiological response caused by infection with group A type B hemolytic streptococci.
The anti-virus medicine for acute hepatitis is prepared with recombinant DNA leucocyte interferon (IFN- α) to inhibit HBV replication, and through intramuscular injection for 6 months, only 30-50% of patients obtain lasting effect, and the first choice of hepatitis C medicine is interferon capable of being combined with ribavirin ② lamivudine, which is a synthesized dideoxycytidine medicine with anti-HBV effect, orally taken lamivudine, serum HBV-DNA level can be obviously reduced, HBV-DNA conversion rate reaches 90% or more after 12 weeks.
Chronic hepatitis B is very difficult to treat and is a consensus of medical circles at home and abroad, and at present, no specific medicine for treating chronic hepatitis B exists.
Disclosure of Invention
The invention aims to improve the defects of the prior art and provide the traditional Chinese medicine composition for treating hepatitis B, which can effectively improve or even eliminate the clinical symptoms of patients and has the characteristics of obvious treatment effect, short treatment period, no toxic or side effect and the like.
Hepatitis B arthritis belongs to the category of bone impediment, stubborn arthralgia, wangbi, historical arthritis and the like in the traditional Chinese medicine. The rheumatism mainly occurs when internal injury occurs to the liver, spleen and kidney, if the qi of yin and yang of human body is unbalanced, the preponderance and decline appear, the wind, cold and damp evil invade the human body, the victory of wind qi is migratory arthralgia, and the cold qi is the pain arthralgia; the victory dampness is arthralgia, and wind-cold-dampness obstructs meridians and joints, resulting in pain and swelling of joints. The rheumatism usually progresses in a chronic way, and if the disease lasts for a long time, the pathogenic factors enter the interior from the exterior, and the pathogenic factors are mild and severe, which causes dysfunction of the viscera and blood stasis, and the condition of the disease is lingering and difficult to treat. Therefore, it should invigorate spleen and warm middle energizer, tonify kidney and strengthen bone, expel wind and remove dampness, relax tendons and activate collaterals, activate blood and relieve swelling, remove toxicity and alleviate pain. The human body is regulated as a whole to achieve a new equilibrium state, thereby achieving the purpose of thorough cure.
Based on the theory, the invention provides a traditional Chinese medicine for treating hepatitis B, which is prepared from the following raw material medicines in parts by weight: 1-3 parts by weight of catechu; 5-10 parts by weight of nutgall, rhizoma cimicifugae and pseudo-ginseng; 7-15 parts of silybum marianum; 10-20 parts of trichosanthes root and giant knotweed; 15-30 parts of penthorum chinense pursh, ampelopsis grossedentata, evodia lepta, blumea balsamifera and ricefield eel vine.
In a preferred embodiment, the traditional Chinese medicine composition for treating hepatitis B consists of the following raw material medicines in parts by weight: 3 parts of catechu; 10 parts by weight of nutgall, rhizoma cimicifugae and pseudo-ginseng; 15 parts of silybum marianum; 20 parts of trichosanthes root and giant knotweed; penthorum chinense pursh, ampelopsis grossedentata, evodia lepta, blumea balsamifera and ricefield eel vine 30 parts by weight.
Wherein, trichosanthes root: sweet, slightly bitter and slightly cold. It enters lung and stomach meridians. Clear heat and promote fluid production, relieve swelling and expel pus. Trichosanthis radix has obvious inhibitory effect on hepatitis B virus, etc., and increases with the increase of the concentration of Tianfen protein.
Nutgall: is bitter in taste; and (4) temperature. Entering the lung; a spleen; the kidney channel. Astringing intestines; securing essence; relieving cough; hemostasis is carried out; and (5) healing the sore. Gallic acid has good anti-HBV effect.
Penthorum chinense pursh: sweet and warm in flavor. Induce diuresis to remove dampness, dispel stasis to alleviate pain. The penthorum chinense pursh obviously resists hepatitis B virus, and obviously or extremely obviously reduces the overall level of DHBY-DNA titer.
The catechu is bitter and astringent, slightly cold, enters lung meridian, astringes dampness, promotes tissue regeneration, heals sore, protects liver, benefits gallbladder, contains d-catechin and epicatechin both have obvious liver protection function, can obviously reduce alanine aminotransferase (A L T), reverse inverted albumin/globulin (A/G), increase glutathione s-transferase (GST) activity and enhance liver detoxification function, has strong inhibition on leukocyte migration of patients who have infected hepatitis B and are sensitive to hepatitis B surface antigen, and can amplify cell-mediated immune reaction to promote the elimination of hepatitis B antigen.
B, ampelopsis: is bitter in taste; and (6) cooling. Returning to the heart; liver; the kidney channel. Clearing heat and promoting diuresis; stasis dissipating and bleeding stopping; detoxicate, remarkably reduce alanine aminotransferase and aspartate aminotransferase, and has effects of protecting liver, lowering transaminase, and resisting free radical.
Bitter taste and cold taste, clear away heat and toxic material, disperse blood stasis and relieve pain, obviously reduce the contents of glutamic-pyruvic transaminase A L T, glutamic-oxaloacetic transaminase AST and liver homogenate malondialdehyde, improve the activity of the GSH-Px of the liver and have obvious high-dose effect.
The cimicifuga foetida is pungent, slightly sweet, slightly cold, enters lung, spleen, stomach and large intestine channels, releases the exterior, promotes eruption, clears away heat and toxic material, and raises yang qi, and can obviously reduce the values of aspartate Aminotransferase (AST) and alanine aminotransferase (A L T) in serum, obviously improve liver injury, and reduce the degeneration and necrosis of liver cells.
Big wind and Chinese mugwort: pungent, slightly bitter and slightly warm. Dispel wind and alleviate swelling, activate blood and dissipate blood stasis. The blumea balsamifera can reduce serum alanine aminotransferase and triglyceride in liver, and obviously reduce pathological damage of liver tissue.
Giant knotweed rhizome: slightly bitter and slightly cold. It enters liver, gallbladder and lung meridians. Dispel wind and remove dampness, dissipate blood stasis and relieve pain, relieve cough and resolve phlegm. The 20% rhizoma Polygoni Cuspidati solution has obvious effect in inhibiting hepatitis B antigen (HBAg). The giant knotweed monomer I and II can reduce the antigen titer of hepatitis B by 8 times.
Silybum marianum: bitter and cool. Clearing away heat and toxic material, protecting liver, promoting function of gallbladder, protecting brain, and resisting X-ray. Can be used for treating chronic hepatitis; cirrhosis, fatty liver; cholelithiasis; cholangitis, and the like. Silybum marianum is a traditional Chinese herbal medicine for protecting liver and reducing transaminase, and has definite curative effect particularly on the aspect of resisting liver injury. Has good curative effect on liver and gall diseases such as acute or chronic hepatitis, cirrhosis, fatty liver, metabolic poisoning liver injury, cholelithiasis, cholangitis and perihepatitis of hepatobiliary duct, and is a liver protection medicine with high drug effect, low toxicity and no side effect. Can rapidly improve subjective symptoms and certain biochemical indexes of patients with liver diseases, such as serum bilirubin, coefficients of Baiwan and wan, thromboplastin, glutamic-pyruvic transaminase, etc.
And (3) ricefield eel vines: sweet in taste; astringency; and (5) slightly warming. Liver diseases entering; the gallbladder meridian. Dispelling wind and removing dampness; promoting blood circulation to arrest pain. Can be used for treating hepatitis; cirrhosis of the liver, and the like.
Pseudo-ginseng is sweet in taste, slightly bitter and warm, enters liver and stomach meridians, dissipates stasis to stop bleeding, reduces swelling and relieves pain, and the pseudo-ginseng has the effect of resisting liver injury, can obviously reduce the activities of serum glutamic-pyruvic transaminase, glutamic-oxalacetic transaminase AST and lactate dehydrogenase (L DH) of liver injury, can relieve liver steatosis and inflammatory cell infiltration, relieves degeneration and necrosis of liver cells, and reduces the hyperplasia of collagen fibroblasts and collagen among the liver cells.
Cimicifugae rhizoma, Notoginseng radix, Monopteri albi vine, and herba Silybi Mariani can relieve hepatocyte inflammation, prevent cell necrosis, prevent hepatic fibrosis, repair liver pathological tissue injury, and promote hepatocyte regeneration.
The invention is prepared from Chinese traditional herbal medicines, and according to the principles of traditional Chinese medicine dialectical treatment and modern medicine, the traditional Chinese medicine for effectively treating hepatitis B is combined by orderly matching certain natural extracts with determined components and clear effects, and the traditional Chinese medicine can effectively prevent liver cirrhosis.
The invention can run through the whole process of hepatitis B treatment, treats both principal and secondary aspects of diseases, is not easy to relapse, is safe and reliable, has no obvious toxic and side effects, is convenient for patients to insist on taking for a long time, has no adverse reaction for the patients after taking the medicine for years, and tracks the blood examination to be normal.
The traditional Chinese medicine composition has the advantages of easily available raw materials, simple process, low cost and high efficiency, and is beneficial to pharmaceutical enterprises for medicine production and quality control; the product has low price and is easy to be accepted by patients.
The traditional Chinese medicine composition has a remarkable effect of treating hepatitis B, and clinical experiment results show that the prescription is used for treatment, one dose is taken every day, 100 ml of water is decocted, the dose is divided into two parts, one part is taken in the morning and at night, one month is taken as a treatment course, generally, one treatment course has effects, three treatment courses can be obviously improved, and the functions of six treatment courses are basically cured. The cure rate is 86% after 6 treatment courses, and the total effective rate is 100%.
The invention also provides an oral preparation prepared from the traditional Chinese medicine composition for treating hepatitis B, which comprises oral liquid, tablets, capsules, pills and the like, wherein the preferable dosage forms are tablets and capsules, and one dose is taken every day in the morning and at night.
The traditional Chinese medicine composition can be prepared into various dosage forms. For example, the decocted liquid medicine is sterilized and disinfected and then packaged to prepare oral liquid; or concentrating the decoction, oven drying, adding pharmaceutically acceptable adjuvants, and making into tablet, capsule, pill, etc.
The medically acceptable auxiliary materials comprise starch, dextrin, sodium carboxymethylcellulose, polyethylene glycol, calcium hydrophosphate, sodium alginate, potassium sorbate and the like.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention in any way, and it will be apparent to those skilled in the art that the above description of the present invention can be applied to various modifications, equivalent variations or modifications without departing from the spirit and scope of the present invention.

Claims (4)

1. The traditional Chinese medicine for treating hepatitis B is characterized by consisting of the following raw material medicines in parts by weight: 1-3 parts by weight of catechu; 5-10 parts by weight of nutgall, rhizoma cimicifugae and pseudo-ginseng; 7-15 parts of silybum marianum; 10-20 parts of trichosanthes root and giant knotweed; 15-30 parts of penthorum chinense pursh, ampelopsis grossedentata, evodia lepta, blumea balsamifera and ricefield eel vine.
2. The traditional Chinese medicine for treating hepatitis B according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 3 parts of catechu; 10 parts by weight of nutgall, rhizoma cimicifugae and pseudo-ginseng; 15 parts of silybum marianum; 20 parts of trichosanthes root and giant knotweed; penthorum chinense pursh, ampelopsis grossedentata, evodia lepta, blumea balsamifera and ricefield eel vine 30 parts by weight.
3. An oral preparation for treating hepatitis B, which is characterized by being prepared from the traditional Chinese medicine composition of any one of claims 1 or 2.
4. The oral preparation for treating hepatitis B according to claim 3, which is characterized by comprising oral liquid, tablets, capsules and pills, and preferably oral liquid and tablets.
CN202010464482.1A 2020-05-28 2020-05-28 A Chinese medicinal composition for treating hepatitis B Pending CN111419956A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010464482.1A CN111419956A (en) 2020-05-28 2020-05-28 A Chinese medicinal composition for treating hepatitis B
CN202110536835.9A CN113209198A (en) 2020-05-28 2021-05-18 A Chinese medicinal composition for treating hepatitis B

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010464482.1A CN111419956A (en) 2020-05-28 2020-05-28 A Chinese medicinal composition for treating hepatitis B

Publications (1)

Publication Number Publication Date
CN111419956A true CN111419956A (en) 2020-07-17

Family

ID=71558968

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010464482.1A Pending CN111419956A (en) 2020-05-28 2020-05-28 A Chinese medicinal composition for treating hepatitis B
CN202110536835.9A Withdrawn CN113209198A (en) 2020-05-28 2021-05-18 A Chinese medicinal composition for treating hepatitis B

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110536835.9A Withdrawn CN113209198A (en) 2020-05-28 2021-05-18 A Chinese medicinal composition for treating hepatitis B

Country Status (1)

Country Link
CN (2) CN111419956A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113209198A (en) * 2020-05-28 2021-08-06 仲崇允 A Chinese medicinal composition for treating hepatitis B

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419956A (en) * 2020-05-28 2020-07-17 仲崇允 A Chinese medicinal composition for treating hepatitis B

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113209198A (en) * 2020-05-28 2021-08-06 仲崇允 A Chinese medicinal composition for treating hepatitis B

Also Published As

Publication number Publication date
CN113209198A (en) 2021-08-06

Similar Documents

Publication Publication Date Title
CN1081067C (en) Chinese medicine prescription for curing hepatitis, cholangitis, pancreatitis and cirrhosis
CN1304744A (en) Chinese medicine for curing hepatitis B and cirrhosis ascites
CN111419956A (en) A Chinese medicinal composition for treating hepatitis B
CN1720965A (en) Chinese medicinal composition for treating acute icterohepatitis
CN103142920A (en) Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof
CN1060938C (en) Chinese medicinal instant powder for treatment of B-hepatitis
CN1985902B (en) Chinese medicine for treating chronic hepatopathy
CN102861198B (en) Pure traditional Chinese medicine preparation for treating cirrhosis with ascites
CN112494550A (en) A Chinese medicinal composition for relieving hangover and treating alcoholic liver
CN1056301C (en) 'Lanweiling' oral liquid for treating appendicitis
CN111643561A (en) A Chinese medicinal composition for treating menoxenia, dysmenorrhea, and amenorrhea
CN105396017A (en) Traditional Chinese medicine preparation used for treating fatty liver, and preparation method thereof
CN111420013A (en) A Chinese medicinal composition for treating cholecystitis, cholangitis and cholelithiasis
CN1092970C (en) Compound Chinese medicine for treating hepatocholepathy
CN112494627B (en) Traditional Chinese medicine composition for treating exogenous fever as well as preparation method and application thereof
CN106620074A (en) Traditional Chinese medicine for treating periodontitis and preparation method thereof
CN112439041A (en) Traditional Chinese medicine composition for treating toxic hepatitis
CN101057903A (en) Traditional Chinese medicine preparation for curing acute eczema
CN106236971A (en) A kind of Chinese medicine composition treating chronic nephritis
CN105663850A (en) Traditional Chinese medicine composition for treating oral ulcer
CN105663832A (en) Traditional Chinese medicine composition for treating radiodermatitis
CN111419969A (en) Traditional Chinese medicine composition for treating osteomyelitis
CN105055665A (en) Anti-hepatoma traditional Chinese medicine preparation
CN111759908A (en) Traditional Chinese medicine composition for treating urticaria
CN104127709A (en) Traditional Chinese medicinal composition for curing chronic renal insufficiency

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200717

WD01 Invention patent application deemed withdrawn after publication